Please login to the form below

Not currently logged in
Email:
Password:

Nimbus looks to Merck for CEO

Donald Nicholson spent 26 years at US pharma giant

merck donald nicholsonNimbus has appointed Merck & Co's Donald Nicholson as the company's new CEO.

Nicholson spent 26 years at Merck holding various strategic leadership and operational roles in diverse therapeutic areas including respiratory inflammation immunology bone endocrine urology infectious diseases and neurosciences.

He began his career in 1988 at the Merck-Frost Centre for Therapeutic Research in Montreal.

In his new role at Nimbus Nicholson will lead a US biotech with a portfolio of programmes in immunology oncology and metabolic diseases targeting mechanisms that have been traditionally difficult or intractable. The company is expected to enter human clinical trials in early 2015.

It is thrilling to join the company at such a watershed moment as the lead programs move toward clinical development,” said Dr Nicholson. “I look forward to working with such a highly respected team of colleagues Board members and investors to deliver the greatest value of the portfolio to patients.”

1st October 2014

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics